Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

FDA News, New FDA Approvals
March 6, 2018
A+ A-
Email Print

Article Link: Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

PRINCETON, N.J.–(BUSINESS WIRE) March 6, 2018 –Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab)…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post